Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
Kenneth Carl Anderson, Daniel Auclair, Stacey J. Adam et al. · Clinical Cancer Research · 2021
The development of novel agents has transformed the treatment paradigm for multiple myeloma, with minimal residual disease (MRD) negativity now achievable across the entire disease spectrum. Bone marrow-based technologies to assess MRD, including approaches using next-generation flow and next-generation sequencing, have provided real-time clinical tools for the sensitive detection and monitoring of MRD in patients with multiple myeloma. Complementary liquid biopsy-based assays are now quickly progressing with some, such as mass spectrometry methods, being very close to clinical use, while others utilizing nucleic acid-based technologies are still developing and will prove important to further our understanding of the biology of MRD. On the regulatory front, multiple retrospective individual patient and clinical trial level meta-analyses have already shown and will continue to assess the potential of MRD as a surrogate for patient outcome. Given all this progress, it is not surprising that a number of clinicians are now considering using MRD to inform real-world clinical care of patients across the spectrum from smoldering myeloma to relapsed refractory multiple myeloma, with each disease setting presenting key challenges and questions that will need to be addressed through clinical trials. The pace of advances in targeted and immune therapies in multiple myeloma is unprecedented, and novel MRD-driven biomarker strategies are essential to accelerate innovative clinical trials leading to regulatory approval of novel treatments and continued improvement in patient outcomes.
Cited by 66 works. doi:10.1158/1078-0432.ccr-21-1059 Open-access PDF
Authors
- Kenneth Carl Anderson
- Daniel Auclair
- Stacey J. Adam
- Amit Agarwal
- Hervé Avet‐Loiseau
- Mark W. Bustoros
- Jessica R. Chapman
- Dana E. Connors
- Ajeeta B. Dash
- Alessandra Di Bacco
- Thierry T.F. Facon
- Juan A Flores-Montero
- Francesca Gay
- Irene M. Ghobrial
- Nicole J. Gormley
- Ira V Gupta
- Howard R. Higley
- Jens Hillengaß
References
- Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging.
- Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- Immunoglobulin gene rearrangement and cell surface antigen expression in acute lymphocytic leukemias of T cell and B cell precursor origins.
- Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
- Using synthetic templates to design an unbiased multiplex PCR assay
- Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
- Current and future perspectives of liquid biopsies in genomics-driven oncology
- Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders